OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis $0.03 0.00 (-0.39%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Mateon Therapeutics Stock (OTCMKTS:MATN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mateon Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.02▼$0.0452-Week Range$0.13▼$0.38Volume299,872 shsAverage Volume338,444 shsMarket Capitalization$2.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mateon Therapeutics, Inc. is a biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on treatments designed to target tumor blood vessels and disrupt the vascular systems that support cancer growth. Mateon’s development programs have included OXi4503, an investigational vascular-disrupting agent derived from combretastatin technology. The compound has been studied for potential use in oncology indications, including acute myeloid leukemia and solid tumors. The company has also explored additional therapeutic applications and programs in response to emerging medical needs. Mateon Therapeutics was formerly known as OXiGENE, Inc. and adopted its current name as its business strategy evolved. Publicly available information about its current operations, leadership, geographic reach and commercial products is limited, and its programs remain primarily development-stage rather than marketed therapies.AI Generated. May Contain Errors. Read More Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MATN Stock News HeadlinesSorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummaryFebruary 25, 2023 | benzinga.comSee More Headlines MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed this year? Mateon Therapeutics' stock was trading at $0.0784 at the start of the year. Since then, MATN stock has decreased by 67.7% and is now trading at $0.0253. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), BioLineRx (BLRX). Company Calendar Last Earnings5/15/2019Today9/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year Founded1996Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.13Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$2.28 million OptionableNot Optionable Beta1.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:MATN) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mateon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
